MAVENCLAD® INDICATIONS AND CONTRAINDICATIONS
MAVENCLAD®: for patients with highly active relapsing multiple sclerosis
MAVENCLAD® is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.1
In the CLARITY trial this included:
- Patients with 1 relapse in the previous year and at least 1 T1 Gd+ lesion or 9 or more T2 lesions, while on therapy with other DMDs
- Patients with 2 or more relapses in the previous year, whether on DMD treatment or not
Contraindications to MAVENCLAD®1
- Moderate or severe renal impairment (creatinine clearance <60 mL/min)
- Hypersensitivity to cladribine or any excipient listed on the Summary of Product Characteristics (SPC)
- HIV infection
- Active chronic infection (tuberculosis or hepatitis)
- Immunocompromised patients, including those receiving immunosuppressive or myelosuppressive therapy
- Active malignancy
- Pregnancy and breast-feeding
Refer to the summary of product characteristics for complete prescribing information